Zhejiang University CAR-T cell therapy

This investigational CAR-T cell therapy is being developed by Zhejiang University for the treatment of relapsed and refractory hematological malignancies, specifically those presenting with extramedullary lesions. The therapeutic approach involves a sequential regimen where localized radiotherapy is followed by the infusion of autologous T cells genetically engineered to express chimeric antigen receptors (CARs) targeting tumor-associated antigens. The specific CAR-T product used is determined by the patient's tumor profile, typically targeting antigens such as CD19 for B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia, or BCMA for multiple myeloma. By combining radiotherapy with cell therapy, the treatment aims to improve outcomes in patients with difficult-to-treat extramedullary disease by debulking tumors and enhancing the systemic anti-tumor immune response.

Other names

Sequential radiotherapy with CAR-T cellsCAR-T cells